Serotonin transporter gene-linked polymorphic region: Possible pharmacogenetic implications of rare variants

Enrico Smeraldi, Alessandro Serretti, Paola Artioli, Cristina Lorenzi, Marco Catalano

Research output: Contribution to journalArticle

Abstract

A functional insertion/deletion (*l/*s) repeat polymorphism within the promoter region of the serotonin transporter (5-HTTLPR) has been described. An association between *l variant and a better and faster response to serotonin selective reuptake inhibitors in depressed patients was reported in Caucasians. The value of the explained variance due to the 5-HTTLPR, however, was 7% only, and different *l and *s variants were reported according to the nucleotide sequence of repeats. In this study, we investigated the antidepressant response to fluvoxamine in individuals carrying different *l and *s variants according to the Nakamura findings. Two hundred and twenty-eight patients affected by bipolar disorder and major depression were administered a daily dose of fluvoxamine up to 300 mg and evaluated at baseline and weekly thereafter until week 7, using the 21-item Hamilton Rating Scale for Depression. We found a marginally significant difference in genotype and allele (P=0.04, data not shown) distribution (*l and *s traditional variants) according to diagnosis (bipolar disorder vs. major depression). We confirmed a better and faster response in our depressed patients bearing the *l variant, but we also found significant differences in response among *l carriers according to the type of *l allele. In fact, 16F *l carriers showed only a partial response, while 16D *l carriers showed a marginally significantly better response than 16A *l allele carriers. These results, although very preliminary, can represent a further step toward a better understanding of the molecular genetics of antidepressant response.

Original languageEnglish
Pages (from-to)153-158
Number of pages6
JournalPsychiatric Genetics
Volume16
Issue number4
DOIs
Publication statusPublished - Aug 2006

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Pharmacogenetics
Fluvoxamine
Alleles
Depression
Bipolar Disorder
Antidepressive Agents
Genes
Serotonin Uptake Inhibitors
Genetic Promoter Regions
Molecular Biology
Genotype

Keywords

  • 5-HTTLPR
  • Depression
  • Fluvoxamine
  • Pharmacogenetics
  • Serotonin transporter
  • Treatment response

ASJC Scopus subject areas

  • Genetics(clinical)
  • Psychiatry and Mental health
  • Genetics
  • Neuroscience(all)

Cite this

Serotonin transporter gene-linked polymorphic region : Possible pharmacogenetic implications of rare variants. / Smeraldi, Enrico; Serretti, Alessandro; Artioli, Paola; Lorenzi, Cristina; Catalano, Marco.

In: Psychiatric Genetics, Vol. 16, No. 4, 08.2006, p. 153-158.

Research output: Contribution to journalArticle

Smeraldi, Enrico ; Serretti, Alessandro ; Artioli, Paola ; Lorenzi, Cristina ; Catalano, Marco. / Serotonin transporter gene-linked polymorphic region : Possible pharmacogenetic implications of rare variants. In: Psychiatric Genetics. 2006 ; Vol. 16, No. 4. pp. 153-158.
@article{a6e8f1b63db5479889786066bdbae53c,
title = "Serotonin transporter gene-linked polymorphic region: Possible pharmacogenetic implications of rare variants",
abstract = "A functional insertion/deletion (*l/*s) repeat polymorphism within the promoter region of the serotonin transporter (5-HTTLPR) has been described. An association between *l variant and a better and faster response to serotonin selective reuptake inhibitors in depressed patients was reported in Caucasians. The value of the explained variance due to the 5-HTTLPR, however, was 7{\%} only, and different *l and *s variants were reported according to the nucleotide sequence of repeats. In this study, we investigated the antidepressant response to fluvoxamine in individuals carrying different *l and *s variants according to the Nakamura findings. Two hundred and twenty-eight patients affected by bipolar disorder and major depression were administered a daily dose of fluvoxamine up to 300 mg and evaluated at baseline and weekly thereafter until week 7, using the 21-item Hamilton Rating Scale for Depression. We found a marginally significant difference in genotype and allele (P=0.04, data not shown) distribution (*l and *s traditional variants) according to diagnosis (bipolar disorder vs. major depression). We confirmed a better and faster response in our depressed patients bearing the *l variant, but we also found significant differences in response among *l carriers according to the type of *l allele. In fact, 16F *l carriers showed only a partial response, while 16D *l carriers showed a marginally significantly better response than 16A *l allele carriers. These results, although very preliminary, can represent a further step toward a better understanding of the molecular genetics of antidepressant response.",
keywords = "5-HTTLPR, Depression, Fluvoxamine, Pharmacogenetics, Serotonin transporter, Treatment response",
author = "Enrico Smeraldi and Alessandro Serretti and Paola Artioli and Cristina Lorenzi and Marco Catalano",
year = "2006",
month = "8",
doi = "10.1097/01.ypg.0000218611.53064.a0",
language = "English",
volume = "16",
pages = "153--158",
journal = "Psychiatric Genetics",
issn = "0955-8829",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Serotonin transporter gene-linked polymorphic region

T2 - Possible pharmacogenetic implications of rare variants

AU - Smeraldi, Enrico

AU - Serretti, Alessandro

AU - Artioli, Paola

AU - Lorenzi, Cristina

AU - Catalano, Marco

PY - 2006/8

Y1 - 2006/8

N2 - A functional insertion/deletion (*l/*s) repeat polymorphism within the promoter region of the serotonin transporter (5-HTTLPR) has been described. An association between *l variant and a better and faster response to serotonin selective reuptake inhibitors in depressed patients was reported in Caucasians. The value of the explained variance due to the 5-HTTLPR, however, was 7% only, and different *l and *s variants were reported according to the nucleotide sequence of repeats. In this study, we investigated the antidepressant response to fluvoxamine in individuals carrying different *l and *s variants according to the Nakamura findings. Two hundred and twenty-eight patients affected by bipolar disorder and major depression were administered a daily dose of fluvoxamine up to 300 mg and evaluated at baseline and weekly thereafter until week 7, using the 21-item Hamilton Rating Scale for Depression. We found a marginally significant difference in genotype and allele (P=0.04, data not shown) distribution (*l and *s traditional variants) according to diagnosis (bipolar disorder vs. major depression). We confirmed a better and faster response in our depressed patients bearing the *l variant, but we also found significant differences in response among *l carriers according to the type of *l allele. In fact, 16F *l carriers showed only a partial response, while 16D *l carriers showed a marginally significantly better response than 16A *l allele carriers. These results, although very preliminary, can represent a further step toward a better understanding of the molecular genetics of antidepressant response.

AB - A functional insertion/deletion (*l/*s) repeat polymorphism within the promoter region of the serotonin transporter (5-HTTLPR) has been described. An association between *l variant and a better and faster response to serotonin selective reuptake inhibitors in depressed patients was reported in Caucasians. The value of the explained variance due to the 5-HTTLPR, however, was 7% only, and different *l and *s variants were reported according to the nucleotide sequence of repeats. In this study, we investigated the antidepressant response to fluvoxamine in individuals carrying different *l and *s variants according to the Nakamura findings. Two hundred and twenty-eight patients affected by bipolar disorder and major depression were administered a daily dose of fluvoxamine up to 300 mg and evaluated at baseline and weekly thereafter until week 7, using the 21-item Hamilton Rating Scale for Depression. We found a marginally significant difference in genotype and allele (P=0.04, data not shown) distribution (*l and *s traditional variants) according to diagnosis (bipolar disorder vs. major depression). We confirmed a better and faster response in our depressed patients bearing the *l variant, but we also found significant differences in response among *l carriers according to the type of *l allele. In fact, 16F *l carriers showed only a partial response, while 16D *l carriers showed a marginally significantly better response than 16A *l allele carriers. These results, although very preliminary, can represent a further step toward a better understanding of the molecular genetics of antidepressant response.

KW - 5-HTTLPR

KW - Depression

KW - Fluvoxamine

KW - Pharmacogenetics

KW - Serotonin transporter

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=33748431550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748431550&partnerID=8YFLogxK

U2 - 10.1097/01.ypg.0000218611.53064.a0

DO - 10.1097/01.ypg.0000218611.53064.a0

M3 - Article

C2 - 16829782

AN - SCOPUS:33748431550

VL - 16

SP - 153

EP - 158

JO - Psychiatric Genetics

JF - Psychiatric Genetics

SN - 0955-8829

IS - 4

ER -